Several other analysts also recently weighed in on the stock. Shore Capital restated a hold rating on shares of AstraZeneca in a research report on Monday, March 5th. Goldman Sachs Group set a GBX 3,750 ($51.81) price objective on shares of AstraZeneca and gave the stock a sell rating in a research report on Friday, March 2nd. Citigroup restated a buy rating and set a GBX 6,200 ($85.66) price objective on shares of AstraZeneca in a research report on Thursday, March 1st. JPMorgan Chase & Co. restated an overweight rating and set a GBX 5,500 ($75.99) price objective on shares of AstraZeneca in a research report on Tuesday, February 27th. Finally, Jefferies Group set a GBX 5,075 ($70.12) price objective on shares of AstraZeneca and gave the stock a neutral rating in a research report on Monday, February 26th. Four equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating, twelve have given a buy rating and one has assigned a strong buy rating to the company’s stock. The company presently has an average rating of Hold and an average price target of GBX 5,199.70 ($71.84).
Shares of AstraZeneca (LON AZN) opened at GBX 4,784 ($66.10) on Friday. The firm has a market cap of $61,000.00 and a P/E ratio of 2,814.12. AstraZeneca has a 12-month low of GBX 4,260 ($58.86) and a 12-month high of GBX 5,520 ($76.26).
In other AstraZeneca news, insider Philip A. J. Broadley bought 415 shares of the business’s stock in a transaction dated Friday, February 2nd. The shares were acquired at an average cost of GBX 4,846 ($66.95) per share, with a total value of £20,110.90 ($27,785.16).
ILLEGAL ACTIVITY WARNING: This story was posted by Ticker Report and is the sole property of of Ticker Report. If you are accessing this story on another publication, it was illegally stolen and reposted in violation of US and international trademark and copyright law. The legal version of this story can be read at https://www.tickerreport.com/banking-finance/3256720/astrazenecas-azn-top-pick-rating-reiterated-at-barclays.html.
AstraZeneca Company Profile
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.